Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma

References

• DeAngelis LM, Seiferheld W, Schold SC, . Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 2002;20:4643–4648.
   PubMed Web of Science ®Google Scholar
• Herrlinger U, Kuker W, Uhl M, . NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol 2005;57:843–847.
   PubMed Web of Science ®Google Scholar
• Guha-Thakurta N, Damek D, Pollack C, . Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients. J Neurooncol 1999;43:259–268.
   PubMed Web of Science ®Google Scholar
• Pels H, Schmidt-Wolf IG, Glasmacher A, . Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 2003;21:4489–4495.
   PubMed Web of Science ®Google Scholar
• Shah GD, Yahalom J, Correa DD, . Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 2007;25:4730–4735.
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Reni M, Foppoli M, . High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 2009;374:1512–1520.
   PubMed Web of Science ®Google Scholar
• Keuzenkamp-Jansen CW, De Abreu RA, Blom HJ, . Effects on transmethylation by high-dose 6-mercaptopurine and methotrexate infusions during consolidation treatment of acute lymphoblastic leukemia. Biochem Pharmacol 1996;51:1165–1171.
   PubMed Web of Science ®Google Scholar
• Barnes MJ, Estlin EJ, Taylor GA, . Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines. Clin Cancer Res 1999;5:2548–2558.
   PubMed Web of Science ®Google Scholar
• Yoon SA, Choi JR, Kim JO, . Influence of reduced folate carrier and dihydrofolate reductase genes on methotrexate-induced cytotoxicity. Cancer Res Treat 2010;42:163–171.
   PubMedGoogle Scholar
• Sanchez-del-Campo L, Montenegro MF, Cabezas-Herrera J, . The critical role of alpha-folate receptor in the resistance of melanoma to methotrexate. Pigment Cell Melanoma Res 2009;22:588–600.
   PubMed Web of Science ®Google Scholar
• Li WW, Waltham M, Tong W, . Increased activity of gamma-glutamyl hydrolase in human sarcoma cell lines: a novel mechanism of intrinsic resistance to methotrexate (MTX). Adv Exp Med Biol 1993;338:635–638.
   PubMedGoogle Scholar
• Morales C, Garcia MJ, Ribas M, . Dihydrofolate reductase amplification and sensitization to methotrexate of methotrexate-resistant colon cancer cells. Mol Cancer Ther 2009;8:424–432.
   PubMed Web of Science ®Google Scholar
• Blakley RL, Sorrentino BP. In vitro mutations in dihydrofolate reductase that confer resistance to methotrexate: potential for clinical application. Hum Mutat 1998;11:259–263.
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Dell’Oro S, Capello D, . Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas. Br J Haematol 2004;126:657–664.
   PubMed Web of Science ®Google Scholar
• Jolivet J, Cowan KH, Curt GA, . The pharmacology and clinical use of methotrexate. N Engl J Med 1983;309:1094–1104.
   PubMed Web of Science ®Google Scholar
• Erttmann R, Bielack S, Landbeck G. Kinetics of 7-hydroxy-methotrexate after high-dose methotrexate therapy. Cancer Chemother Pharmacol 1985;15:101–104.
   PubMed Web of Science ®Google Scholar
• Stoller RG, Hande KR, Jacobs SA, . Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med 1977;297:630–634.
   PubMed Web of Science ®Google Scholar
• Borsi JD, Sagen E, Romslo I, . Pharmacokinetics and metabolism of methotrexate: an example for the use of clinical pharmacology in pediatric oncology. Pediatr Hematol Oncol 1990;7:13–33.
   PubMed Web of Science ®Google Scholar
• Maiguma T, Hayashi Y, Ueshima S, . Relationship between oral mucositis and high-dose methotrexate therapy in pediatric acute lymphoblastic leukemia. Int J Clin Pharmacol Ther 2008;46:584–590.
   PubMed Web of Science ®Google Scholar
• Joerger M, Huitema AD, van den Bongard HJ, . Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. Br J Clin Pharmacol 2006;62:71–80.
   PubMed Web of Science ®Google Scholar
• Goorin A, Strother D, Poplack D, . Safety and efficacy of l-leucovorin rescue following high-dose methotrexate for osteosarcoma. Med Pediatr Oncol 1995;24:362–367.
   PubMedGoogle Scholar
• Von Hoff DD, Penta JS, Helman LJ, . Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration. Cancer Treat Rep 1977;61:745–748.
   PubMedGoogle Scholar
• Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist 2006;11:694–703.
   PubMed Web of Science ®Google Scholar
• Pauley JL, Panetta JC, Schmidt J, . Late-onset delayed excretion of methotrexate. Cancer Chemother Pharmacol 2004;54:146–152.
   PubMed Web of Science ®Google Scholar
• Relling MV, Stapleton FB, Ochs J, . Removal of methotrexate, leucovorin, and their metabolites by combined hemodialysis and hemoperfusion. Cancer 1988;62:884–888.
   PubMed Web of Science ®Google Scholar
• Saland JM, Leavey PJ, Bash RO, . Effective removal of methotrexate by high-flux hemodialysis. Pediatr Nephrol 2002;17:825–829.
   PubMed Web of Science ®Google Scholar
• Widemann BC, Balis FM, Murphy RF, . Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction. J Clin Oncol 1997;15:2125–2134.
   PubMed Web of Science ®Google Scholar
• Titier K, Lagrange F, Pehourcq F, . Pharmacokinetic interaction between high-dose methotrexate and oxacillin. Ther Drug Monit 2002;24:570–572.
   PubMed Web of Science ®Google Scholar
• Frei E 3rd, Blum RH, Pitman SW, . High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. Am J Med 1980;68:370–376.
   PubMed Web of Science ®Google Scholar
• Pinto PC, Hu E, Bernstein-Singer M, . Acute hepatic injury after the withdrawal of immunosuppressive chemotherapy in patients with hepatitis B. Cancer 1990;65:878–884.
   PubMed Web of Science ®Google Scholar
• Weber BL, Tanyer G, Poplack DG, . Transient acute hepatotoxicity of high-dose methotrexate therapy during childhood. NCI Monogr 1987:207–212.
   PubMedGoogle Scholar
• Chen PM, Chiou TJ, Fan FS, . Fulminant hepatitis is significantly increased in hepatitis B carriers after allogeneic bone marrow transplantation. Transplantation 1999;67:1425–1433.
   PubMed Web of Science ®Google Scholar
• Wong GC, Tan P, Goh YT, . Exacerbation of hepatitis in hepatitis B carriers following chemotherapy for haematological malignancies. Ann Acad Med Singapore 1996;25:500–503.
   PubMedGoogle Scholar
• Yeo W, Chan PK, Zhong S, . Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000;62:299–307.
   PubMed Web of Science ®Google Scholar
• Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006;43:209–220.
   PubMed Web of Science ®Google Scholar
• Cheng A-L, Yeh K-H, Uen W-C, . Systemic chemotherapy alone for patients with non-acquired immunodeficiency syndrome-related central nervous system lymphoma. Cancer 1998;82:1946–1951.
   PubMed Web of Science ®Google Scholar
• Blay JY, Conroy T, Chevreau C, . High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 1998;16:864–871.
   PubMed Web of Science ®Google Scholar
• Treon SP, Chabner BA. Concepts in use of high-dose methotrexate therapy. Clin Chem 1996;42:1322–1329.
   PubMed Web of Science ®Google Scholar
• Kerr IG, Jolivet J, Collins JM, . Test dose for predicting high-dose methotrexate infusions. Clin Pharmacol Ther 1983;33:44–51.
   PubMed Web of Science ®Google Scholar
• Joerger M, Huitema AD, Krahenbuhl S, . Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: a pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer 2010;102:673–677.
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Guerra E, Regazzi M, . Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br J Cancer 2004;90:353–358.
   PubMed Web of Science ®Google Scholar
• Jacobs SA, Stoller RG, Chabner BA, . Dose-dependent metabolism of methotrexate in man and rhesus monkeys. Cancer Treat Rep 1977;61:651–656.
   PubMedGoogle Scholar
• Sasaki K, Tanaka J, Fujimoto T. Theoretically required urinary flow during high-dose methotrexate infusion. Cancer Chemother Pharmacol 1984;13:9–13.
   PubMed Web of Science ®Google Scholar
• Pitman SW, Frei E 3rd. Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma. Cancer Treat Rep 1977;61:695–701.
   PubMedGoogle Scholar
• Thyss A, Milano G, Kubar J, . Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet 1986;1:256–258.
   PubMed Web of Science ®Google Scholar
• Ferrazzini G, Klein J, Sulh H, . Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia. J Pediatr 1990;117:823–826.
   PubMed Web of Science ®Google Scholar
• Dalle JH, Auvrignon A, Vassal G, . Interaction between methotrexate and ciprofloxacin. J Pediatr Hematol Oncol 2002;24:321–322.
   PubMed Web of Science ®Google Scholar
• Blum R, Seymour JF, Toner G. Significant impairment of high-dose methotrexate clearance following vancomycin administration in the absence of overt renal impairment. Ann Oncol 2002;13:327–330.
   PubMed Web of Science ®Google Scholar
• Corcino J, Waxman S, Herbert V. Mechanism of triamterene-induced megaloblastosis. Ann Intern Med 1970;73:419–424.
   PubMed Web of Science ®Google Scholar
• Richmond R, McRorie ER, Ogden DA, . Methotrexate and triamterene—a potentially fatal combination? Ann Rheum Dis 1997;56:209–210.
   PubMed Web of Science ®Google Scholar
• Crews KR, Zhou Y, Pauley JL, . Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia. Cancer 2010;116:227–232.
   PubMed Web of Science ®Google Scholar
• Santucci R, Leveque D, Lescoute A, . Delayed elimination of methotrexate associated with co-administration of proton pump inhibitors. Anticancer Res 2010;30:3807–3810.
   PubMed Web of Science ®Google Scholar
• Wolff JE, Hauch H, Kuhl J, . Dexamethasone increases hepatotoxicity of MTX in children with brain tumors. Anticancer Res 1998;18:2895–2899.
   PubMed Web of Science ®Google Scholar
• Fuksa L, Brcakova E, Kolouchova G, . Dexamethasone reduces methotrexate biliary elimination and potentiates its hepatotoxicity in rats. Toxicology 2010;267:165–171.
   PubMed Web of Science ®Google Scholar
• Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2003;2:404–409.
   PubMed Web of Science ®Google Scholar
• Relling MV, Pui CH, Sandlund JT, . Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet 2000;356:285–290.
   PubMed Web of Science ®Google Scholar
• Li J, Gwilt P. The effect of malignant effusions on methotrexate disposition. Cancer Chemother Pharmacol 2002;50:373–382.
   PubMed Web of Science ®Google Scholar
• Raude E, Oellerich M, Weinel P, . High-dose methotrexate: pharmacokinetics in children and young adults. Int J Clin Pharmacol Ther Toxicol 1988;26:364–370.
   PubMedGoogle Scholar
• Wolfrom C, Hepp R, Hartmann R, . Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue. Eur J Clin Pharmacol 1990;39:377–383.
   PubMed Web of Science ®Google Scholar
• Pignon T, Lacarelle B, Duffaud F, . Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma. Cancer Chemother Pharmacol 1994;33:420–424.
   PubMed Web of Science ®Google Scholar
• Comandone A, Passera R, Boglione A, . High dose methotrexate in adult patients with osteosarcoma: clinical and pharmacokinetic results. Acta Oncol 2005;44:406–411.
   PubMed Web of Science ®Google Scholar
• Johansson AM, Hill N, Perisoglou M, . A population pharmacokinetic/pharmacodynamic model of methotrexate and mucositis scores in osteosarcoma. Ther Drug Monit 2011;33:711–718.
   PubMed Web of Science ®Google Scholar
• Lai R, Rosenblum MK, DeAngelis LM. Primary CNS lymphoma: a whole-brain disease? Neurology 2002;59:1557–1562.
   PubMed Web of Science ®Google Scholar
• Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 1975;293:161–166.
   PubMed Web of Science ®Google Scholar
• Freeman AI, Wang JJ, Sinks LF. High-dose methotrexate in acute lymphocytic leukemia. Cancer Treat Rep 1977;61:727–731.
   PubMedGoogle Scholar
• Glantz MJ, Cole BF, Recht L, . High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol 1998;16:1561–1567.
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Reni M, Dell’Oro S, . Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients. Oncology 2001;60:134–140.
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Reni M, Pasini F, . A multicenter study of treatment of primary CNS lymphoma. Neurology 2002;58:1513–1520.
   PubMed Web of Science ®Google Scholar
• Markowsky SJ, Zimmerman CL, Tholl D, . Methotrexate disposition following disruption of the blood-brain barrier. Ther Drug Monit 1991;13:24–31.
   PubMed Web of Science ®Google Scholar
• Angelov L, Doolittle ND, Kraemer DF, . Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience. J Clin Oncol 2009;27:3503–3509.
   PubMed Web of Science ®Google Scholar
• Zylber-Katz E, Gomori JM, Schwartz A, . Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma. Clin Pharmacol Ther 2000;67:631–641.
   PubMed Web of Science ®Google Scholar
• Neuwelt EA, Diehl JT, Vu LH, . Monitoring of methotrexate delivery in patients with malignant brain tumors after osmotic blood-brain barrier disruption. Ann Intern Med 1981;94:449–454.
   PubMed Web of Science ®Google Scholar
• Marcus R, Hodson D, Coupland S, . British Committee for Standards in Haematology. Guidelines on the diagnosis and management of adult patients with primary CNS lymphoma (CNSL) and primary intra-ocular lymphoma (PIOL). 2009. Available from: http://www.bcshguidelines.com/documents/PCNSL__bcsh_2007.pdf
   Google Scholar
• Motl S, Zhuang Y, Waters CM, . Pharmacokinetic considerations in the treatment of CNS tumours. Clin Pharmacokinet 2006;45:871–903.
   PubMed Web of Science ®Google Scholar
• Herrlinger U, Schabet M, Brugger W, . German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. Ann Neurol 2002;51:247–252.
   PubMed Web of Science ®Google Scholar
• Hiraga S, Arita N, Ohnishi T, . Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas. J Neurosurg 1999;91:221–230.
   PubMed Web of Science ®Google Scholar
• Miyauchi Y, Mii Y, Morishita T, . [A device for rapid elevation of plasma methotrexate (MTX) concentration and its maintenance in high-dose MTX therapy]. Gan To Kagaku Ryoho 1996;23:595–599.
   PubMedGoogle Scholar
• Duttera MJ, Bleyer WA, Pomeroy TC, . Irradiation, methotrexate toxicity, and the treatment of meningeal leukaemia. Lancet 1973;2:703–707.
   PubMed Web of Science ®Google Scholar
• DeAngelis LM, Yahalom J, Thaler HT, . Combined modality therapy for primary CNS lymphoma. J Clin Oncol 1992;10:635–643.
   PubMed Web of Science ®Google Scholar
• Cohen IJ, Vogel R, Matz S, . Successful non-neurotoxic therapy (without radiation) of a multifocal primary brain lymphoma with a methotrexate, vincristine, and BCNU protocol (DEMOB). Cancer 1986;57:6–11.
   PubMed Web of Science ®Google Scholar
• Bleyer WA, Drake JC, Chabner BA. Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia. N Engl J Med 1973;289:770–773.
   PubMed Web of Science ®Google Scholar
• Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol 1998;16:859–863.
   PubMed Web of Science ®Google Scholar
• Ott RJ, Brada M, Flower MA, . Measurements of blood-brain barrier permeability in patients undergoing radiotherapy and chemotherapy for primary cerebral lymphoma. Eur J Cancer 1991;27:1356–1361.
   PubMed Web of Science ®Google Scholar
• Abrey LE, Moskowitz CH, Mason WP, . Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 2003;21:4151–4156.
   PubMed Web of Science ®Google Scholar
• Kiewe P, Fischer L, Martus P, . Primary central nervous system lymphoma: monocenter, long-term, intent-to-treat analysis. Cancer 2008;112:1812–1820.
   PubMed Web of Science ®Google Scholar
• Thiel E, Korfel A, Martus P, . High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 2010;11:1036–1047.
   PubMed Web of Science ®Google Scholar
• Batchelor T, Carson K, O’Neill A, . Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 2003;21:1044–1049.
   PubMed Web of Science ®Google Scholar
• Gerstner ER, Carson KA, Grossman SA, . Long-term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiation. Neurology 2008;70:401–402.
   PubMed Web of Science ®Google Scholar
• Blasco H, Senecal D, Le Gouge A, . Influence of methotrexate exposure on outcome in patients treated with MBVP chemotherapy for primary central nervous system lymphoma. Br J Clin Pharmacol 2010;70:367–375.
   PubMed Web of Science ®Google Scholar
• Morris PG, Abrey LE, Reiner AS, . Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapy. Leuk Lymphoma 2011;52:1891–1897.
   PubMed Web of Science ®Google Scholar